At the interface
Sphingolipids, or SLs, have emerged as critical players in membrane stability and as essential signaling molecules. SLs range from abundant species involved in maintaining membrane integrity, such as sphingomyelin, to scarce and potent signaling species, such as sphingosine-1-phosphate, or S1P. S1P mediates critical signaling functions through interaction with its cognate G-protein coupled receptors in development and in several disease states. In recent decades, many resources have been devoted to understanding how S1P generation is regulated.
S1P can be generated through the action of two sphingosine kinase isoforms. The more commonly expressed of the two is sphingosine kinase 1, or SK1. This enzyme has garnered attention as a potential therapeutic target, as it often is upregulated in diseases such as cancer. To gain access to its substrate, sphingosine, and to release its product, S1P, SK1 must interact directly with membranes. However, how SK1 achieves membrane binding has been contested in the literature. How does a cytosolic lipid-metabolizing enzyme without any lipid-binding domains interact with membranes to access its substrate?
![](http://www.asbmb.org/imagearchive/79354/Lipid-news-fig-1.jpg)
Previously, researchers thought SK1 translocation was dependent on other proteins. However, recent data show how SK1 can bind directly to membranes. SK1 possesses an intrinsic interface composed of two motifs: one electrostatic motif and one hydrophobic motif. Using biochemical methods, we found that these two motifs are necessary for membrane interaction, thus implicating their function as a single entity. Using hydrogen deuterium exchange mass spectrometry, we confirmed that SK1 employs a single contiguous interface that contains the two motifs. In cancer cells, disruption of this interface causes loss of membrane association and decreases SK1 activity. Past research has shown that interaction with membranes is critical for mediating SK1-dependent biologies including tumor cell invasion and endocytosis. This could provide a new avenue for targeting SK1 in diseases. Inhibition of membrane binding would deny SK1 access to its substrate, thereby inhibiting all activity.
Recent research shows an important role for SK1 in endocytic trafficking. SK1 presence at endocytic membranes would require membrane binding and curvature sensing. However, how SK1 can do this is largely unknown. Analysis of the atomic structure of SK1 revealed a potential dimerization interface. Such dimerization would align the membrane-binding interface of each SK1 monomer. This would strengthen the interaction and potentially allow for physical curvature sensing by SK1. This remains to be validated, but it’s an exciting hypothesis. Another way to potentially inhibit activity would be to inhibit dimerization, if that is required for activity and membrane binding.
Significant strides have been made in understanding the structure and function of many SL metabolizing enzymes, and exciting questions remain to be answered, especially for SK1. How can SK1 decipher the difference between the charges of different anionic phospholipids? How does the catalytic cycle progress once SK1 is at the membrane? Is dimerization required for membrane binding/curvature sensing? What role is the hydrophobic patch playing in curvature sensing?
Biophysical, biochemical and structural research will reveal the secrets of how SL enzymes work and how they might be exploited for therapeutic development.
Enjoy reading ASBMB Today?
Become a member to receive the print edition monthly and the digital edition weekly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles
![The quest to treat and cure xerostomia](/getmedia/09045019-5c58-4434-9eb0-d6be609842cb/Xerostomia-thumb.jpg?width=480&height=270&ext=.jpg)
The quest to treat and cure xerostomia
Blake Warner, chief of the Salivary Disorders Unit at the NIH talks about his lab’s efforts to develop treatments for dry mouth.
![There's more to blue cheese than just the stench](/getmedia/65d1751a-27b4-405b-9210-8cde34249ef5/More-to-blue-cheese-480x270.jpg?width=480&height=270&ext=.jpg)
There's more to blue cheese than just the stench
Virginia Tech researchers discovered a way to synthesize a compound in the mold of blue cheese that has antibacterial and anticancer properties.
![Engineering cells to broadcast their behavior can help scientists study their inner workings](/getmedia/a5c8da38-1a39-4183-be72-85d5cbff8a29/Engeneering-cells-to-broadcast-480x270.jpg?width=480&height=270&ext=.jpg)
Engineering cells to broadcast their behavior can help scientists study their inner workings
Researchers can use waves to transmit signals from the invisible processes and dynamics underlying how cells make decisions.
![From the journals: JBC](/getmedia/a3620094-c80e-41b9-91ab-22037b087112/FTJ-JBC-07-19-24-480x270.jpg?width=480&height=270&ext=.jpg)
From the journals: JBC
Lung cancer cells resist ferroptosis. ORMDL3 in ulcerative colitis. Novel genetic variants in thyroid cancer. Read about these recent papers.
![Seeking the sweet spot to beat a pig parasite](/getmedia/30869767-881b-438b-9f19-531ef9eee79e/Pig-parasite-480x270.jpg?width=480&height=270&ext=.jpg)
Seeking the sweet spot to beat a pig parasite
Researchers extracted, separated and tested glycans from the porcine whipworm in an effort to determine the best way to develop treatments and vaccines.
![Radioactive drugs strike cancer with precision](/getmedia/f3a6418b-340a-43cc-b53f-30916dbbd8f4/Radioactive-drugs-strike-cancer-480x270.jpg?width=480&height=270&ext=.jpg)
Radioactive drugs strike cancer with precision
The tumor-seeking radiopharmaceuticals are charting a new course in oncology, with promise for targeted treatments with fewer side effects.